HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GDC-0425

structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - GDC-0425: 2
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - GDC-0425: 2

Experts

1.	Chen, Yuan: 2 articles (05/2017 - 12/2016)
2.	Ding, Xiao: 2 articles (05/2017 - 12/2016)
3.	Sahasranaman, Srikumar: 2 articles (05/2017 - 12/2016)
4.	Bauer, Todd M: 1 article (05/2017)
5.	Blackwood, Elizabeth M: 1 article (05/2017)
6.	Evangelista, Marie: 1 article (05/2017)
7.	Hollebecque, Antoine: 1 article (05/2017)
8.	Infante, Jeffrey R: 1 article (05/2017)
9.	Lauchle, Jennifer O: 1 article (05/2017)
10.	LoRusso, Patricia M: 1 article (05/2017)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2016 - "This assay was used to characterize the pharmacokinetics of GDC-0425 in cancer patients." 05/15/2017 - "This phase I study evaluated the Chk1 inhibitor GDC-0425 given in combination with gemcitabine to patients with advanced solid tumors.Experimental" 05/15/2017 - "Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors."
2.	Thrombocytopenia (Thrombopenia) 05/15/2017 - "The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each). "
3.	Syncope (Fainting) 05/15/2017 - "The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each). "
4.	Neutropenia 05/15/2017 - "The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each). "
5.	Nausea 05/15/2017 - "The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each). "

Related Drugs and Biologics

1.	Gemcitabine
2.	Checkpoint Kinase 1
3.	Alanine Transaminase (SGPT)